Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.09 USD
Change Today +0.03 / 0.37%
Volume 38.4K
As of 8:04 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc (MDGN) Snapshot

Open
$8.07
Previous Close
$8.06
Day High
$8.11
Day Low
$8.00
52 Week High
01/29/15 - $8.50
52 Week Low
12/4/14 - $3.68
Market Cap
201.0M
Average Volume 10 Days
49.4K
EPS TTM
$-0.96
Shares Outstanding
24.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDGENICS INC (MDGN)

Related News

No related news articles were found.

medgenics inc (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc (MDGN) Details

Medgenics, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. It develops transduced autologous restorative gene therapy, TARGT platform to provide protein and peptide therapies to treat a range of chronic diseases and conditions. The company’s lead product candidate is MDGN-201, which is in the Phase I/II clinical trials for the treatment of end stage renal disease. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

40 Employees
Last Reported Date: 02/13/15
Founded in 2000

medgenics inc (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $765.0K
Chief Financial Officer
Total Annual Compensation: $565.0K
Chief Legal Officer
Total Annual Compensation: $154.0K
Chief Scientific Officer
Total Annual Compensation: $660.0K
Compensation as of Fiscal Year 2014.

medgenics inc (MDGN) Key Developments

Medgenics, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 02:30 PM

Medgenics, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 02:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Medgenics, Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Medgenics, Inc. announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported a loss of $6.20 million or $0.30 per share, compared with a loss of $5.21 million or $0.28 per share for the comparative quarter in 2013. For the period, the company reported operating loss of $12,628,000 against $17,818,000 a year ago. Loss before taxes on income was $15,052,000 against $17,112,000 a year ago. Loss was $15,071,000 or $1.37 per diluted share against $17,129,000 or $1.06 per diluted share a year ago.

Medgenics, Inc. Presents at 27th Annual ROTH Conference, Mar-09-2015 10:30 AM

Medgenics, Inc. Presents at 27th Annual ROTH Conference, Mar-09-2015 10:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $8.09 USD +0.03

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies
 

Industry Analysis

MDGN

Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC, please visit www.medgenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.